Phylogica Ltd

Phylogica’s approach to developing peptide-based therapeutics give many advantages over conventional strategies for biopharmaceutical drug development, particularly antibody-based therapies. The Phylomer® Libraries compete directly against a panel of alternate peptide screening technologies, the most common being the random peptide libraries. Advantages of Phylogica’s Phylomers® over random peptide libraries include better hit rates, higher stability and greater structural diversity.

Further Information: http://www.phylogica.com/